Business Today: Latest Business News, India economy News, Stock Markets, Sensex, Mutual Funds and Indian Tax
Search

Total 76 results found. Search for [ Malvinder%20Mohan%20Singh ]

Results 1 to 21 of 76
www.businesstoday.in
February 17, 2018



www.businesstoday.in
February 17, 2018



www.businesstoday.in
February 14, 2018



BusinessToday.in
New Delhi, February 13, 2018
Fortis says that apart from paying Rs 65.98 lakh fine to stock exchanges for \"non-submission of un-audited financial results\", the reports emerging in the media had \"enhanced the scope of limited review audit by the statutory auditors\".


PTI
New Delhi, February 10, 2018
Fortis Healthcare was issued notices by the stock exchanges yesterday following a media report claiming that the company's promoters, the Singh bothers, took at least Rs 500 crore without board approval about a year ago.


BusinessToday.in
New Delhi, February 9, 2018
The duo quit as directors from the company's board on Thursday. The company issued a release saying the resignation is \"intended to free the organisation from any encumbrances that may be linked to the promoters in light of the recent HC judgement.\"


BusinessToday.in
February 9, 2018
Days after the Delhi High Court verdict dealt a body blow to Fortis Healthcare promoters - Malvinder Mohan Singh and Shivinder Mohan Singh - by upholding the Rs 3,500 crore arbitral award in favour of Daiichi Sankyo, the duo have quit as directors from the company's board


www.businesstoday.in
February 9, 2018



BusinessToday.in
February 9, 2018
At 12:29 pm, the stock was trading 12.09% or 15.25 points higher at 141.35 level in an otherwise falling market. The stock hit an intra day high of 157.05 level and a low of 123.10 level. It is down 11.53% since the beginning of this year. On  an yearly basis, the stock has fallen 28.71% on BSE.


www.businesstoday.in
February 8, 2018



BT Guest Columnist
New Delhi, February 6, 2018
With the Delhi High Court's verdict, Daiichi Sankyo has scored a victory against former Ranbaxy promoters. But it won't end there.


BusinessToday.in
New Delhi, February 8, 2018
Fortis Healthcare promoters Malvinder Mohan Singh and Shivinder Mohan Singh, also called Singh Brothers, on Thursday resigned as directors from the company's board days after the Delhi High Court order upheld the Rs 3,500 crore arbitral award in favour of Daiichi Sankyo.


Team BT
January 18, 2017
Delhi High Court is hearing a plea from Japanese drug major Daiichi Sankyo, to prevent the erstwhile promoters of Ranbaxy pharmaceuticals - brothers Malvinder Mohan Singh and Shivinder Mohan Singh - from diluting their stake in Fortis Healthcare.


PB Jayakumar
Delhi, November 26, 2016
Many global healthcare chains and investors are pumping money into hospitals in India. This may prove to be a game changer for the country's healthcare sector.


Dipak Mondal
Delhi, November 12, 2016
Some international arbitration cases that have gone against India highlight the uncertainty in the country's policy and regulatory framework.


Joe C Mathew
May 6, 2016
Breach of faith, dreams turned sour and a $5.35 billion hole in the pocket. That, in substance, was the Japanese pharma major Daiichi-Sankyo's failed India sojourn that began in June, 2008 and packed up in April, 2014.


BusinessToday.in
May 5, 2016
Billionaire businessman Malvinder Mohan Singh and his younger brother Shivinder Mohan Singh have been fined nearly Rs 2,600 crore, media reports say. The erstwhile promoters of drug maker Ranbaxy were penalised for concealing and misrepresenting facts from Japanese pharmaceutical major Daiichi Sankyo.


PB Jayakumar
Delhi, April 16, 2016
Dr. Tan See Leng, Managing Director and Chief Executive Officer of IHH Healthcare and Group Chief Executive Officer and Managing Director of Parkway, spoke to BT's P.B. Jayakumar on plans for India, Fortis' takeover attempt and investing in Apollo.


BT Guest Columnist
February 29, 2016
The Finance Minister has done well by recognising the importance of a healthy population.


Team BT
Delhi, February 27, 2016
\"Moves towards ensuring simplified procedures with time-bound accountability for approvals will go a long way in driving growth,\" says Dr Reddy's Laboratories Co-Chairman and CEO G.V. Prasad.


PAGES 1 OF 4  1234